Revisión narrativa de la terapia inhalatoria en la EPOC

  1. A.L. Aguilar-Shea 1
  2. C. Gallardo-Mayo 2
  1. 1 Centro de Salud Puerta de Madrid, Atención Primaria de Madrid, Madrid, España
  2. 2 Anestesiología, Reanimación y Terapia del Dolor, Hospital Universitario Infanta Leonor, Madrid, España
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Año de publicación: 2022

Número: 3

Páginas: 214-218

Tipo: Artículo

DOI: 10.1016/J.SEMERG.2021.08.001 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Semergen: revista española de medicina de familia

Objetivos de desarrollo sostenible

Resumen

La terapia inhalada con broncodilatadores de acción larga es la base del tratamiento farmacológico de la EPOC. Con el fin conocer los que ofrecen un mejor control, se realizó una búsqueda en Medline (Pubmed). Se analizaron los estudios comparativos de terapia inhaladora en pacientes con EPOC. Tras la comparación entre la combinación fija LABA/LAMA frente LABA/CI en pacientes no exacerbadores, se concluye que hay un mejor control con LABA/LAMA. Dentro de las combinaciones LABA/CI, la combinación budesonida/formoterol ofreció un mejor control. En la terapia LAMA no hay grandes diferencias, pero comparada con LABA ofreció un mayor control. La triple terapia en un único dispositivo se muestra superior a la doble terapia y a la triple terapia en dos dispositivos, no habiendo diferencias relevantes entre las combinaciones disponibles.

Referencias bibliográficas

  • M. Miravitlles, M. Calle, J. Molina, P. Almagro, J.T. Gómez, J.A. Trigueros, et al. Spanish COPD Guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD Arch Bronconeumol (Engl Ed). (2021), 10.1016/j.arbres.2021.03.005 View PDFGoogle Scholar
  • M. Reza Maleki-Yazdi, M. Molimard, D.L. Keininger, J.B. Gruenberger, J. Carrasco, C. Pitotti, et al. Cost effectiveness of the long-acting β2-adrenergic agonist (LABA)/long-acting muscarinic antagonist dual bronchodilator indacaterol/glycopyrronium versus the LABA/inhaled corticosteroid combination salmeterol/fluticasone in patients with chronic obstructive pulmonary disease: Analyses conducted for Canada, France, Italy, and Portugal Appl Health Econ Health Policy., 14 (2016), pp. 579-594 View PDFCrossRefView Record in ScopusGoogle Scholar
  • J.A. Wedzicha, D. Banerji, K.R. Chapman, J. Vestbo, N. Roche, R.T. Ayers, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD N Engl J Med., 374 (2016), pp. 2222-2234 View PDFCrossRefView Record in ScopusGoogle Scholar
  • N. Horita, N. Miyazawa, K. Tomaru, M. Inoue, T. Kaneko Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis Respirology., 20 (2015), pp. 1153-1159 View PDFCrossRefView Record in ScopusGoogle Scholar
  • N. Zhong, C. Wang, X. Zhou, N. Zhang, M. Humphries, L. Wang, et al. LANTERN: A randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD Int J Chron Obstruct Pulmon Dis., 10 (2015), pp. 1015-1026 View Record in ScopusGoogle Scholar
  • D. Price, D. Keininger, M. Costa-Scharplatz, K. Mezzi, M. Dimova, Y. Asukai Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting Respir Med., 108 (2014), pp. 1786-1793 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.C. Samp, M.J. Joo, G.T. Schumock, G.S. Calip, A.S. Pickard, T.A. Lee Comparative effectiveness of long-acting beta2-agonist combined with a long-acting muscarinic antagonist or inhaled corticosteroid in chronic obstructive pulmonary disease Pharmacotherapy., 37 (2017), pp. 447-455, 10.1002/phar.1913 View PDFView Record in ScopusGoogle Scholar
  • J.A. Wedzicha, N. Zhong, M. Ichinose, M. Humphries, R. Fogel, C. Thach, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: Results from the FLAME study Int J Chron Obstruct Pulmon Dis., 12 (2017), pp. 339-349, 10.2147/COPD.S125058 View PDFView Record in ScopusGoogle Scholar
  • C. Vogelmeier, N. Zhong, M.J. Humphries, K. Mezzi, R. Fogel, G. Bader, et al. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis Int J Chron Obstruct Pulmon Dis., 11 (2016), pp. 3189-3197, 10.2147/COPD.S116786 View PDFView Record in ScopusGoogle Scholar
  • N. Zhong, C. Wang, X. Zhou, N. Zhang, M. Humphries, L. Wang, et al. Efficacy and safety of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone in Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: The Chinese cohort from the LANTERN study COPD., 13 (2016), pp. 686-692 View PDFCrossRefView Record in ScopusGoogle Scholar
  • N. Horita, A. Goto, Y. Shibata, E. Ota, K. Nakashima, K. Nagai, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD) Cochrane Database Syst Rev, Issue2 (2017), 10.1002/14651858.CD012066.pub2 CD012066 View PDFGoogle Scholar
  • J.A. Wedzicha, D. Singh, I. Tsiligianni, C. Jenkins, S. Fucile, R. Fogel, et al. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: A post-hoc analysis in the FLAME study Respir Res., 20 (2019), p. 4, 10.1186/s12931-019-0972-7 View PDFView Record in ScopusGoogle Scholar
  • A.R. Anzueto, K. Kostikas, K. Mezzi, S. Shen, M. Larbig, F. Patalano, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: Results from the FLAME study Respir Res., 19 (2018), p. 121, 10.1186/s12931-018-0830-z View PDFView Record in ScopusGoogle Scholar
  • C.F. Vogelmeier, K.R. Chapman, M. Miravitlles, N. Roche, J. Vestbo, C. Thach, et al. Exacerbation heterogeneity in COPD: Subgroup analyses from the FLAME study Int J Chron Obstruct Pulmon Dis., 13 (2018), pp. 1125-1134, 10.2147/COPD.S160011 View PDFView Record in ScopusGoogle Scholar
  • M.C. Chan, E.C. Tan, M.C. Yang Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD Int J Chron Obstruct Pulmon Dis., 13 (2018), pp. 1079-1088, 10.2147/COPD.S159103 View PDFView Record in ScopusGoogle Scholar
  • L. Calzetta, F. di Marco, F. Blasi, M. Cazzola, S. Centanni, C. Micheletto, et al. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis Pulm Pharmacol Ther., 59 (2019), p. 101855, 10.1016/j.pupt.2019.101855 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • E. Yip, S. Karimi, L.T. Pien Evaluation of a therapeutic interchange from fluticasone/salmeterol to mometasone/formoterol in patients with chronic obstructive pulmonary disease J Manag Care Spec Pharm., 22 (2016), pp. 316-323 View PDFCrossRefView Record in ScopusGoogle Scholar
  • D.M. Kern, J. Davis, S.A. Williams, O. Tunceli, B. Wu, S. Hollis, et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: A US administrative claims database study Respir Res., 16 (2015), p. 52 View Record in ScopusGoogle Scholar
  • D.S. Postma, N. Roche, G. Colice, E. Israel, R.J. Martin, W.M. van Aalderen, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD Int J Chron Obstruct Pulmon Dis., 9 (2014), pp. 1163-1186 View Record in ScopusGoogle Scholar
  • J.A. Ohar, G.D. Crater, A. Emmett, T.J. Ferro, A.N. Morris, I. Raphiou, et al. Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation Respir Res., 15 (2014), p. 105 View Record in ScopusGoogle Scholar
  • K. Larsson, C. Janson, K. Lisspers, L. Jørgensen, G. Stratelis, G. Telg, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: The PATHOS study J Intern Med., 273 (2013), pp. 584-594 View PDFCrossRefView Record in ScopusGoogle Scholar
  • V. Perrone, D. Sangiorgi, S. Buda, L. degli Esposti Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: Findings from a real-world analysis in an Italian setting Int J Chron Obstruct Pulmon Dis., 11 (2016), pp. 2749-2755 View Record in ScopusGoogle Scholar
  • A.L. Aguilar-Shea, J. Bonis COPD from an everyday primary care point of view J Family Med Prim Care., 8 (2019), pp. 2644-2650, 10.4103/jfmpc.jfmpc_477_19 View PDFView Record in ScopusGoogle Scholar
  • P. Solidoro, F. Patrucco, D. Bagnasco Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: A review Expert Rev Respir Med., 13 (2019), pp. 1087-1094, 10.1080/17476348.2019.1665514 View PDFView Record in ScopusGoogle Scholar
  • R.H. Stanford, E.D. Parker, T.K. Reinsch, A.R. Buikema, C. Blauer-Peterson Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA Respir Med., 150 (2019), pp. 1-7, 10.1016/j.rmed.2019.01.019 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • K.M. Beeh, A.M. Kirsten, A.M. Tanase, A. Richard, W. Cao, B. Hederer, et al. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: Results from a Phase II randomized, double-blind 12-week study Int J Chron Obstruct Pulmon Dis., 13 (2018), pp. 3923-3936, 10.2147/COPD.S179293 View PDFView Record in ScopusGoogle Scholar
  • R. Wise, P.M. Calverley, R. Dahl, D. Dusser, N. Metzdorf, A. Müller, et al. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: A post hoc analysis of the TIOSPIR trial NPJ Prim Care Respir Med., 25 (2015), p. 15067 View Record in ScopusGoogle Scholar
  • A.G. Mathioudakis, V. Chatzimavridou-Grigoriadou, E. Evangelopoulou, G.A. Mathioudakis, N.M. Siafakas Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: Are they equivalent? Pulm Pharmacol Ther., 28 (2014), pp. 91-97 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • S. Spila-Alegiani, F. Trotta, R. da Cas, M. Rossi, M. Venegoni, G. Traversa Comparative effectiveness of two tiotropium formulations: A retrospective cohort study COPD., 15 (2018), pp. 418-423, 10.1080/15412555.2018.1554032 View PDFView Record in ScopusGoogle Scholar
  • M. Costa-Scharplatz, B. Ställberg, P. Goyal, Y. Asukai, J.B. Gruenberger, D. Price, et al. Cost-effectiveness of glycopyrronium bromide compared with tiotropium in patients with chronic obstructive pulmonary disease in Sweden Appl Health Econ Health Policy., 13 (2015), pp. 637-645 View PDFCrossRefView Record in ScopusGoogle Scholar
  • T. Kamei, H. Nakamura, N. Nanki, Y. Minakata, K. Matsunaga, Y. Mori, Command Study Group Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: A multicentre, open-label, randomised study BMJ Open., 9 (2019), p. e024114, 10.1136/bmjopen-2018-024114 View PDFView Record in ScopusGoogle Scholar
  • C.F. Vogelmeier, G.M. Asijee, K. Kupas, K.M. Beeh Tiotropium and salmeterol in COPD patients at risk of exacerbations: A post hoc analysis from POET-COPD® Adv Ther., 32 (2015), pp. 537-547 View PDFCrossRefView Record in ScopusGoogle Scholar
  • M.L. Decramer, K.R. Chapman, R. Dahl, P. Frith, G. Devouassoux, C. Fritscher, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study Lancet Respir Med., 1 (2013), pp. 524-533 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • D. Price, Y. Asukai, J. Ananthapavan, B. Malcolm, A. Radwan, I. Keyzor A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use Appl Health Econ Health Policy., 11 (2013), pp. 259-274 View PDFCrossRefView Record in ScopusGoogle Scholar
  • A. Koarai, H. Sugiura, M. Yamada, T. Ichikawa, N. Fujino, T. Kawayama, et al. Treatment with LABA versus LAMA for stable COPD: A systematic review and meta-analysis BMC Pulm Med, 20 (2020), p. 111, 10.1186/s12890-020-1152-8 View PDFView Record in ScopusGoogle Scholar
  • F. Trudo, D.M. Kern, J.R. Davis, O. Tunceli, S. Zhou, E.L. Graham Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments Int J Chron Obstruct Pulmon Dis., 10 (2015), pp. 2055-2066 View Record in ScopusGoogle Scholar
  • S.-N. Yang, H.-K. Ko, Y.-H. Hsiao, K.-C. Su, Y.L. Chang, H.-Y. Huang, et al. Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment J Chin Med Assoc., 82 (2019), pp. 488-494, 10.1097/JCMA.0000000000000114 ArticleDownload PDFGoogle Scholar
  • G.J. Feldman, A.R. Sousa, D.A. Lipson, L. Tombs, N. Barnes, J.H. Riley, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: A randomized study Adv Ther., 34 (2017), pp. 2518-2533, 10.1007/s12325-017-0626-4 View PDFView Record in ScopusGoogle Scholar
  • M.K. Siddiqui, P. Shukla, M. Jenkins, M. Ouwens, D. Guranlioglu, P. Darken, et al. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β 2-agonist fixed-dose combinations in COPD Ther Adv Respir Dis. (2019), 10.1177/1753466619894502 View PDFGoogle Scholar
  • G. Brusselle, D. Price, K. Gruffydd-Jones, M. Miravitlles, D.L. Keininger, R. Stewart, et al. The inevitable drift to triple therapy in COPD: An analysis of prescribing pathways in the UK Int J Chron Obstruct Pulmon Dis, 10 (2015), pp. 2207-2217 View Record in ScopusGoogle Scholar
  • D. Singh, A. Papi, M. Corradi, I. Pavlišová, I. Montagna, C. Francisco, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial Lancet., 388 (2016), pp. 963-973 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Vestbo, A. Papi, M. Corradi, V. Blazhko, I. Montagna, C. Francisco, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A double-blind, parallel group, randomised controlled trial Lancet., 389 (2017), pp. 1919-1929 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • A. Papi, J. Vestbo, L. Fabbri, M. Corradi, H. Prunier, G. Cohuet, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): A double-blind, parallel group, randomised controlled trial Lancet., 391 (2018), pp. 1076-1084 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • P.R. Bremner, R. Birk, N. Brealey, A.S. Ismaila, C.Q. Zhu, D.A. Lipson Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study Respir Res., 19 (2018), p. 19 View Record in ScopusGoogle Scholar
  • D.A. Lipson, F. Barnhart, N. Brealey, J. Brooks, G.J. Criner, N.C. Day, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD N Engl J Med., 378 (2018), pp. 1671-1680 View PDFCrossRefGoogle Scholar
  • N.C. Day, S. Kumar, G. Criner, M. Dransfield, D.M.G. Halpin, M.K. Han, et al. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: Results on cardiovascular safety from the IMPACT trial Respir Res., 21 (2020), p. 139, 10.1186/s12931-020-01398-w View PDFView Record in ScopusGoogle Scholar
  • M. Kato, K. Tomii, K. Hashimoto, Y. Nezu, T. Ishii, C.E. Jones, et al. The IMPACT Study — Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: Efficacy and safety in a Japanese population Int J Chron Obstruct Pulmon Dis., 14 (2019), pp. 2849-2861, 10.2147/COPD.S226601 View PDFView Record in ScopusGoogle Scholar
  • A.S. Ismaila, N. Risebrough, M. Schroeder, D. Shah, A. Martin, E.C. Goodall, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: The IMPACT trial Int J Chron Obstruct Pulmon Dis., 14 (2019), pp. 2681-2695, 10.2147/COPD.S216072 View PDFView Record in ScopusGoogle Scholar
  • S. Suissa, S. dell’Aniello, P. Ernst Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort study in real-world clinical practice Chest., 157 (2020), pp. 846-855, 10.1016/j.chest.2019.11.007 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • G.T. Ferguson, N. Brown, C. Compton, T.C. Corbridge, K. Dorais, C. Fogarty, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials Respir Res., 21 (2020), p. 131, 10.1186/s12931-020-01360-w View PDFView Record in ScopusGoogle Scholar
  • G.T. Ferguson, P. Darken, S. Ballal, M.K. Siddiqui, B. Singh, S. Attri, et al. Efficacy of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) versus other inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β 2-agonist (ICS/LAMA/LABA) triple combinations in COPD: A systematic literature review and network meta-analysis Adv Ther., 37 (2020), pp. 2956-2975, 10.1007/s12325-020-01311-3 View PDFView Record in ScopusGoogle Scholar
  • B. Alcázar-Navarrete, F. Castellano Miñán, P.J. Romero Palacios The future of triple therapy in chronic obstructive pulmonary disease Arch Bronconeumol., 54 (2018), pp. 63-64 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • D.L. Vetrano, A. Zucchelli, E. Bianchini, C. Cricelli, A. Piraino, M. Zibellini, et al. Triple inhaled therapy in COPD patients: Determinants of prescription in primary care Respir Med., 154 (2019), pp. 12-17 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • A. Papi, S. Petruzzelli, S. Vezzoli, G. Georges, L.M. Fabbri Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Eur Respir J., 53 (2019) pii: 1900147 Google Scholar
  • D. Singh, L.M. Fabbri, M. Corradi, G. Georges, A. Guasconi, S. Vezzoli, et al. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation Eur Respir J., 53 (2019), p. 1900235, 10.1183/13993003.00235-2019 View PDFView Record in ScopusGoogle Scholar
Fuente de los datos: Dialnet